Viking Therapeutics, Inc. (VKTX) Trading 11.2% Higher
Viking Therapeutics, Inc. (NASDAQ:VKTX) shares traded up 11.2% during trading on Friday . The stock traded as high as $2.16 and last traded at $2.08. 1,144,426 shares were traded during mid-day trading, an increase of 123% from the average session volume of 513,705 shares. The stock had previously closed at $1.87.
Several research analysts recently commented on the stock. Maxim Group reiterated a “buy” rating and issued a $5.00 target price on shares of Viking Therapeutics in a report on Wednesday. ValuEngine upgraded shares of Viking Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price objective (up previously from $5.00) on shares of Viking Therapeutics in a report on Monday, July 17th.
The stock has a 50-day moving average of $1.47 and a 200-day moving average of $1.47. The company’s market cap is $57.61 million.
Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Analysts forecast that Viking Therapeutics, Inc. will post ($0.82) earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the stock. Sabby Management LLC bought a new position in Viking Therapeutics during the second quarter worth about $525,000. Renaissance Technologies LLC increased its position in Viking Therapeutics by 62.9% during the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after acquiring an additional 102,600 shares during the period. Finally, Virtu KCG Holdings LLC bought a new position in Viking Therapeutics during the second quarter worth about $124,000. 5.67% of the stock is currently owned by institutional investors and hedge funds.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.